Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seagen Inc.    SGEN

SEAGEN INC.

(SGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
179.04(c) 180.37(c) 176.69(c) 175.86(c) 185.75(c) Last
496 557 801 436 654 090 592 832 1 354 024 Volume
+0.78% +0.74% -2.04% -0.47% +5.62% Change
More quotes
Financials (USD)
Sales 2020 2 159 M - -
Net income 2020 595 M - -
Net cash position 2020 1 942 M - -
P/E ratio 2020 56,3x
Yield 2020 -
Sales 2021 1 813 M - -
Net income 2021 -13,9 M - -
Net cash position 2021 2 374 M - -
P/E ratio 2021 -5 067x
Yield 2021 -
Capitalization 33 601 M 33 601 M -
EV / Sales 2020 14,7x
EV / Sales 2021 17,2x
Nbr of Employees 1 605
Free-Float 99,4%
More Financials
Company
Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV... 
More about the company
Notations Surperformance© of Seagen Inc.
Trading Rating : Investor Rating :
More Ratings
All news about SEAGEN INC.
01/15SEAGEN : BofA Securities Upgrades Seagen to Buy from Neutral, Sets $215 Price Ta..
MT
01/07SEAGEN : to Host Conference Call and Webcast Discussion of Fourth Quarter and Fu..
BU
2020SEAGEN : Registers Mixed-Securities Shelf Offering
MT
2020SEAGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020SEAGEN : to Present at the J.P. Morgan Healthcare Conference
BU
2020SEAGEN : Announces Positive CHMP Opinion for TUKYSA for the Treatment of Patient..
AQ
2020Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors
AQ
2020SEAGEN : Says European Regulatory Committee Recommends Approval of Tukysa in Bre..
MT
2020SEAGEN : Announces Positive CHMP Opinion for TUKYSA® (tucatinib) for the Treatme..
BU
2020Boehringer gets into 'guided-missile drugs' with $1.5 billion deal for NBE
RE
2020SEAGEN : Highlights TUKYSA Data in Breast Cancer at Virtual 2020 San Antonio Bre..
AQ
2020SEAGEN : Highlights TUKYSA® (tucatinib) Data in Breast Cancer at Virtual 2020 Sa..
BU
2020SEAGEN : Announces Multiple ADCETRIS® (brentuximab vedotin) Presentations at the..
BU
2020PRESS RELEASE : New data presented at ASH 2020 reinforces the benefit/risk profi..
DJ
2020Didi Chuxing, BYD roll out customized vans for ride-hailing service
RE
More news
News in other languages on SEAGEN INC.
2020US-Konzern Merck & Co übernimmt Krebsforscher Velosbio
2020SEAGEN INC. : publication des résultats trimestriels
2020SEAGEN INC. : Veröffentlichung des Quartalsergebnisses
202010 Biotechs qui font parler d'elles
2020Aktien New York Schluss: Übernahmen bescheren starken Wochenauftakt
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | SGEN | US81181C1045 | MarketScreener
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 198,59 $
Last Close Price 185,75 $
Spread / Highest target 36,7%
Spread / Average Target 6,91%
Spread / Lowest Target -25,7%
EPS Revisions
Managers and Directors
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Robert J. Lechleider Senior Vice President-Clinical Development
Roger D. Dansey Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SEAGEN INC.6.06%33 601
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-8.36%40 715
IQVIA HOLDINGS INC.4.81%36 004
HANGZHOU TIGERMED CONSULTING CO.,LTD0.37%21 655